[Icosapentanoic acid (EPA), docosahexanoic acid (DHA)].
Katsumata
Toshiya
T
Second Department of Internal Medicine, Nippon Medical School.
Katayama
Yasuo
Y
D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000517:prevention & control; D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control; D015415:Biomarkers / Q000097:blood; D015243:Cholesterol, VLDL / Q000096:biosynthesis; D023903:Coronary Restenosis / Q000209:etiology / Q000517:prevention & control; D004281:Docosahexaenoic Acids / Q000097:blood* / Q000494:pharmacology; D015118:Eicosapentaenoic Acid / Q000097:blood* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology / Q000517:prevention & control; D006973:Hypertension / Q000209:etiology / Q000517:prevention & control; D008099:Liver / Q000378:metabolism; D012016:Reference Values; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control; D013928:Thromboxane A2 / Q000096:biosynthesis
D015415:Biomarkers; D015243:Cholesterol, VLDL; D004281:Docosahexaenoic Acids; D013928:Thromboxane A2; D015118:Eicosapentaenoic Acid